OrbiMed Advisors TIL Position
Exited5-Fund ConvergenceOrbiMed Advisors exited their position in Instil Bio, Inc. (TIL) in Q2 2025, after holding the stock for 4 quarters.
The position was first reported in Q3 2024 and has been tracked across 4 quarterly 13F filings.
TIL is a convergence signal: 5 specialist biotech funds hold this stock, suggesting high institutional conviction.
About Instil Bio, Inc.
Instil Bio, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of patients with cancer. The company develops cell therapy of autologous tumor infiltrating lymphocyte (TIL). Its TIL product candidates in pipeline include ITIL-168 for indications, such as melanoma, cutaneous squamous cell carcinoma, non-small cell lung cancer, head and neck squamous cell carcinoma, and cervical cancer; and ITIL-306 to recognize folate receptor alpha (FOLR1) with indications, including gynecological, non-small cell lung cancer, renal caner, and others. The company was incorporated in 2018 and is headquartered in Dallas, Texas.
Full company profile →Short Interest
9.9%
8.3 days to cover
OrbiMed Advisors TIL Position History
Frequently Asked Questions
Does OrbiMed Advisors own TIL?
No. OrbiMed Advisors exited their position in Instil Bio, Inc. (TIL) in Q2 2025. They previously held the stock for 4 quarters.
How many hedge funds own TIL?
5 specialist biotech hedge funds currently hold TIL, including Boxer Capital, Perceptive Advisors, Commodore Capital and 2 more. When 3 or more specialist funds hold the same stock, BiotechEdge flags it as a convergence signal.
When did OrbiMed Advisors first buy TIL?
OrbiMed Advisors's position in TIL was first reported in Q3 2024. 13F filings are reported with a 45-day delay, so the actual purchase may have occurred earlier in the quarter.
Is OrbiMed Advisors's TIL position increasing or decreasing?
OrbiMed Advisors completely exited their TIL position in the most recent quarter.
Get the weekly biotech signal briefing
Fund moves, convergence shifts, insider buys, and catalyst alerts — delivered free every Monday.
TILCompany Page →
All fund holders, insider trades, catalysts, and cash runway
OrbiMed AdvisorsPortfolio →
Full 13F holdings, sector breakdown, and top movers
Drill into any signal
Fund Convergence
See which stocks multiple specialist funds are buying at once
Catalyst Calendar
Every PDUFA date, Phase 3 readout, and AdCom in one view
Insider Trading
When executives buy their own stock — the strongest bullish signal
Cash Runway
Which biotechs are running low on cash and face dilution risk
Short Squeeze
High short interest + fund buying + upcoming catalyst = squeeze setup
Signal Rankings
Every signal in one composite score — ranked by conviction
Biotech Movers
Stocks with the most signal activity right now across all signals
13F Changes
What top biotech funds bought and sold in the latest 13F filing
Want AI context on every signal? Start free trial →